Davion Healthcare PLC - (DAVI) closed at $1.31 on November 5, 2026, down 21.6% from the previous close, on volume of 178,573 shares (30-day average 2,258,548).
Data as of November 5, 2026.
Davion Healthcare PLC Agrees $13.5 Million Acquisition of Profitable US Home Healthcare Business
Globe Newswire (Thu, 29-Oct 7:30 AM ET)
Market Chameleon (Mon, 26-Oct 7:01 AM ET)
Market Chameleon (Mon, 26-Oct 3:50 AM ET)
Davion Healthcare Announces US$25 Million Acquisition of Humaskan Medical Technology IP
Globe Newswire (Mon, 26-Oct 7:30 AM ET)
Davion Healthcare PLC is focus on developing its range of home tests for a range of home test products, to identify potential medical conditions and provide early warning to enable further clinical examination where applicable. It designs, develops, and patents medical products and non-diagnostic devices and then licenses the manufacturing, marketing, sales, and distribution rights for its products to regional or world-wide commercial partners. The company has been operating as a single segment. Its products are BreastCheck, FootFlow, and Testic.
Davion Healthcare PLC - trades on the NASDAQ stock market under the symbol DAVI.
As of November 5, 2026, DAVI stock price declined to $1.31 with 178,573 million shares trading.
DAVI has a market cap of $32.75 million. This is considered a Sub-Micro Cap stock.
DAVI support price is $1.25 and resistance is $2.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DAVI shares will trade within this expected range on the day.
